Background
Introduction
During hospitalization for acute heart failure, renal function and electrolytes are usually closely monitored, as diuretics are known to affect both. Guidelines recommend daily monitoring of blood urea nitrogen (BUN), creatinine, potassium, and sodium during intravenous diuretic therapy. [1] [2] [3] Interestingly, chloride is not mentioned in this list and similarly research studies investigating the role of chloride are scarce, even though chloride, and not sodium, has a predominant role in renal salt sensing mechanisms. 4, 5 Also, tubular glomerular feedback and renin release have been shown to be primarily driven by chloride rather than sodium. 6 Chloride is a critical regulator of sodium transporter pathways through phosphorylation of a family of serine-threonine kinases. 7, 8 Recently, two studies demonstrated a strong, independent association between hypochloremia and an increased risk of mortality in both acute and chronic heart failure. 9, 10 Both of these studies demonstrated that the prognostic value of chloride was greater than that of sodium. Given the influence of chloride on the targets of diuretic therapy, we sought to determine if hypochloremia is associated with reduced diuretic response and decongestion. Reciprocally given the effect of diuretics on chloride homeostasis, we furthermore aimed to evaluate changes in serum chloride and the prognostic significance of these changes.
Methods

Study design and procedures
The study population and design of the Placebo-controlled Randomized Study of the
Selective A1 antagonist Rolofylline for Patients Hospitalized with Acute Decompensated
Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) study has been described in detail previously. 11 The PROTECT study was a large, multicenter, phase III randomized clinical trial, that enrolled 2,033 patients hospitalized for acute heart failure with mild to moderate renal dysfunction. The local ethics committed at each participating center approved the trial, and all patients provided written informed consent. The primary endpoint of treatment success, failure, or no change was neutral, and no effect was seen on 180-day mortality.
At baseline signs and symptoms of heart failure were assessed. Standard laboratory assessments were performed at baseline, day 7, and day 14. Diuretic response was defined as weight change on day 4 per 40 mg of intravenous furosemide (or equivalent doses)
administered from baseline to day 3. 12 Estimated glomerular filtration rate (eGFR) was calculated using the Cockcroft-Gault equation. Hemoconcentration was defined as an increase in hemoglobin from baseline to day 4. Worsening renal function was defined as an increase ≥ 0.3 mg/dL from baseline to day 7 or 14, and a percentage change > 25%. The endpoint selected for this analysis was 180-day mortality.
Chloride
Chloride at baseline was available in 1960 patients (96%), at day 7 in 1814 patients (89%), and at day 14 in 1783 patients (88%). Hypochloremia was defined as a serum chloride concentration ≤ 96 mmol/L. 13 Chloride was missing due to death at 7 and 14 days in 86 patients (4%). Performing the primary analyses in the subgroup of patients without missing chloride data (n=1649) yielded similar results (data not shown).
Statistical analysis
The analyses were performed in the intention to treat population. Table 2 ). Chloride remained significantly associated with diuretic response, even after correction for sodium and bicarbonate levels in addition to potential baseline and in hospital confounders (p<0.001). There was no significant difference in the incidence of worsening renal function over quintiles of chloride.
Results
Baseline chloride and clinical characteristics
Odds ratios for markers of poor decongestion and hypochloremia are shown in figure 1.
Chloride levels and outcome
In univariable Cox regression analysis, lower baseline chloride was associated with a higher risk of 180-day mortality (HR per SD decrease: 1.35 [1.22-1.49], P<0.001), however, after adjusting for baseline sodium, baseline chloride was no longer predictive of mortality (P=0.163) whereas sodium remained significantly associated (P<0.001). Notably, upon multivariable adjustment for baseline characteristics, neither baseline sodium nor chloride remained associated with outcome (Table 3) . Addition of baseline chloride to a multivariable model containing sodium resulted in no improvement in model performance (P=0.627,
Supplementary table 1).
Lower chloride levels at day 7 and day 14 were associated with a higher risk of 180-day mortality in both univariable and multivariable models, whereas day 7 and day 14 sodium levels were not predictive (table 3) . Figure 2 shows the adjusted hazard ratios for sodium and chloride at different time points.
Addition of day 7 or 14 chloride to a multivariable model that included sodium at the same time point, significantly, though modestly improved the c-statistic (from 0.72 to 0.73; P<0.001, for both day 7 and day 14 chloride), and NRI (P<0.01, supplementary table 1).
There was no significant interaction between sodium and chloride at any time point. A significant interaction between day 14 chloride and day 14 bicarbonate was observed where the risk associated with lower chloride was greater in patients with higher levels of bicarbonate. However this did not reduce the predictive value of day 14 chloride on 180-day mortality (supplementary table 2 ).
Change in chloride levels
On average, chloride levels in the overall population were stable over time (supplementary Comparing patients with hypochloremia at baseline and 14 days ( Table 4 ) we find that 45% of patients with hypochloremia at day 1 no longer had hypochloremia by 14 days, and 59% of hypochloremia at day 14 was newly developed (figure 3). The majority of baseline and treatment related parameters were remarkably similar between patients whose hypochloremia was stable, improved, or worsened (table 4) . The most notable difference we found in terms of clinical characteristics between these groups was a significant increase in BUN from day 1 to day 14, and a decrease in eGFR in patients with who developed new hypochloremia at day 14 (table 4) . There was no significant difference in changes in sodium or bicarbonate. Additionally, rolofylline administration was not associated with changes in chloride levels (P=0.782).
Change in chloride and outcomes:
A decrease in chloride from baseline to either day 7 or day 14 were both associated with an increased risk of 180-day mortality irrespective of baseline sodium and baseline chloride levels (supplementary table 3 ). However, the change seemed to be less important than the ultimate level of chloride achieved since after adjustment for day 14 chloride levels the change was no longer significant (supplementary Table 3 
Discussion
The principle findings of this study are that a low serum chloride is associated with a lower diuretic response, less decongestion, and increased mortality. We found that significant changes in serum chloride were very common during the treatment of AHF with approximately half of hypochloremic patients either resolving or developing new hypochloremia. Importantly, baseline hypochloremia that normalized during admission was not associated with adverse outcomes, whereas new or persistent hypochloremia was associated with 2-3 fold increased risk of mortality. Given the important role for chloride in neurohormonal and sodium homeostatic pathways, these associations might suggest that modulation of serum chloride may possibly improve diuretic response and potentially outcomes in patients with acute heart failure.
Chloride and response to therapy
Chloride has a great number of functions in the body, and deregulation of chloride results in a wide range of abnormalities. 15, 16 Chloride has an important role in salt sensing, and seems to be the main driver in the kidneys ability to sense volume overload, as chloride containing solutions, but not non-chloride containing sodium solutions, elicited a response from the kidney. 4, 5 Chloride has also been shown to reduce renin release, in contrast to non-chloride containing sodium salts which do not affect renin levels. 6 The role of chloride in regulation and response to volume retention in acute heart failure, is therefore of great interest as both fluid regulation and renin-angiotensin-aldosterone activation are deregulated in this setting.
Recent evidence suggests an association between chloride and diuretic targets.
Several studies showed that sensing of hypochloride by WNKs (with no lysine K) causes upregulation of the sodium-potassium-chloride cotransporter (NKKC2). 7, 8 Binding of chloride to the active site of WNK inhibits autophosphorylation and therefore decreases the availability of both NKCC2 and NCC and consequently reduces renal salt reabsorption. Both the activity of loop diuretics, the most common therapy in acute heart failure that is prescribed to over 90% of all acute heart failure patients, and thiazide diuretics appear to be regulated by chloride.
In this study, we found a consistent association between lower baseline chloride levels and poor decongestion. We assessed multiple markers of decongestion, such as diuretic response, hemoconcentration, and physician assessed worsening heart failure, and found large difference of these parameters across the quintiles of chloride. We especially observed a remarkable difference in hemoconcentration, which was 20% more prevalent in the highest chloride quintile, compared to the lowest quintile. However, this study is observational and does not allow to assume a causative relationship. It may nonetheless be speculated that repletion of chloride might decrease fluid overload and subsequently improve decongestion, as evidence suggest a direct effect of chloride on reducing salt reabsorption through regulation of sodium transporters. In this scenario chloride itself would be one of the drivers of fluid overload and poor response to therapies. On the other hand chloride depletion could also be a result of therapy and hence be a sign of a more severe heart failure patient. Either mechanistic studies, or interventional chloride studies may be warranted to distinguish between these two possible scenarios.
Chloride levels over time and association with outcome
Despite overall stable levels of chloride over time in our entire study population, we observed great individual variation in chloride levels at different time points, and modest correlations between chloride levels at different time points. The shift in and out of hypochloremia might be a consequence of treatment, as loop diuretics block the NKCC2 in the kidney and generally cause a disproportionate excretion of chloride compared to sodium. 17 As such it is likely that hypochloremia at day 7, and day 14 may at least in part be diuretic treatment induced. In this study we found a greater predictive value of outcome for day 7 and day 14 chloride, compared to baseline chloride. Interestingly, baseline hypochloremia was free from adverse prognostic significance as long as it resolved with treatment, whereas new or persistent hypochloremia was associated with 2-3 fold increase risk of mortality. The possibility that treatment induced changes in chloride are important is further supported by our finding that patients with higher levels of bicarbonate, which is retained by the body in response to chloride wasting, 18 have a higher risk of adverse outcome for any given decrease in chloride, compared to patients with normal bicarbonate levels. The increased impaired outcome associated with new-onset or persistent hypochloremia, compared to resolved baseline hypochloremia suggests that chloride is not just a marker of risk, as this would generate a greater risk associated with baseline hypochloremia, even when it resolved. Conversely our results show that new onset or persistent hypocholoremia carries greater prognostic significance.
Finally, we also found that a decrease in chloride levels over time was independently predictive of adverse outcome. Significance of the change in chloride was however lost after correction for the chloride level achieved at day 7 or day 14, indicating that the final value of chloride achieved contains more prognostic information than the change itself. A multivariable regression analysis for the change in chloride did not find important factors that could explain this change. More speculative, another explanation could be that the resultant chloride after a massive challenge to chloride homeostasis from treatment for acute heart failure is what makes the difference, rather than the change itself. Additional validation of our findings is required, however based on these results prospective studies investigating either chloride sparing therapies, or chloride replacement may be considered.
Limitations
This study is a post hoc analysis of a randomized controlled trial with all limitations as such. Additionally, we did not have long-term follow-up chloride data available and were not able to study whether restoration of chloride levels attenuated the increased risk of adverse outcome over time.
Conclusion
Low baseline chloride was strongly associated with markers of poor decongestion.
Hypochloremia after hospitalization for AHF, but not at baseline was strongly associated with mortality, suggesting the resultant chloride level carries greatest prognostic importance. 
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